2 Growth Stocks That Could Rocket 144% and 202% Higher This Year, According to Wall StreetThe Motley Fool • 01/27/24
SparingVision Reaches Final Dose Escalation Step in PRODYGY Trial with SPVN06 for retinitis pigmentosaGlobeNewsWire • 01/24/24
Intellia Therapeutics Layoffs 2024: What to Know About the Latest NTLA Job CutsInvestorPlace • 01/05/24
Intellia Therapeutics Highlights its Three-Year Strategic Priorities and Anticipated 2024 Key MilestonesGlobeNewsWire • 01/04/24
Intellia Therapeutics Receives European Union Orphan Drug Designation for NTLA-2002, an Investigational In Vivo CRISPR Genome Editing Treatment for Hereditary AngioedemaGlobeNewsWire • 11/14/23